At Janssen Cardiovascular & Metabolism (CVM), we take on the most pervasive diseases that burden hundreds of millions of people and healthcare systems around the world. As part of this long-standing commitment and propelled by our successes in treating type 2 diabetes and thrombosis, we advance highly differentiated therapies that prevent and treat life-threatening cardiovascular, metabolic and retinal diseases.
The prevalence of these diseases is growing, straining patients, their families and healthcare systems. Uncovering new therapies that can improve the quality of life for this large segment of the population is an important endeavor—one which Janssen CVM will continue to lead in the years to come. Our relentless pursuit of innovation across all stages of drug development means patients get the treatments they need as fast as possible.
Our mission is global, local and personal. Together, we can reshape the future of cardiovascular, metabolic and retinal disease prevention and treatment.